S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NASDAQ:BNTC

Benitec Biopharma Stock Forecast, Price & News

$2.91
-0.19 (-6.13 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.91
Now: $2.91
$3.20
50-Day Range
$2.92
MA: $4.14
$5.31
52-Week Range
$2.52
Now: $2.91
$17.39
Volume197,357 shs
Average Volume444,931 shs
Market Capitalization$14.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.

Headlines

Benitec Biopharma plunges 40% on public offering
October 4, 2020 |  seekingalpha.com
Benitec Biopharma plunges 40% on equity offering
October 4, 2020 |  seekingalpha.com
Benitec Biopharma Inc. Common Stock (BNTC)
August 17, 2020 |  nasdaq.com
Benitec Biopharma readies equity offering
August 16, 2020 |  seekingalpha.com
Benitec Announces Results of Scheme Meeting
March 26, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNTC
CUSIPN/A
CIKN/A
Phone61-3-8692-7222
Employees14
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$100,000.00
Cash Flow$2.94 per share
Book Value$19.75 per share

Profitability

Miscellaneous

Market Cap$14.02 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

864th out of 1,968 stocks

Pharmaceutical Preparations Industry

421st out of 772 stocks

Analyst Opinion: 3.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$2.91
-0.19 (-6.13 %)
(As of 03/3/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Benitec Biopharma (NASDAQ:BNTC) Frequently Asked Questions

Is Benitec Biopharma a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Benitec Biopharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Benitec Biopharma stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTC, but not buy additional shares or sell existing shares.
View analyst ratings for Benitec Biopharma
or view top-rated stocks.

What stocks does MarketBeat like better than Benitec Biopharma?

Wall Street analysts have given Benitec Biopharma a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Benitec Biopharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Benitec Biopharma?

Benitec Biopharma saw a increase in short interest in January. As of January 29th, there was short interest totaling 32,100 shares, an increase of 79.3% from the January 14th total of 17,900 shares. Based on an average daily volume of 586,400 shares, the short-interest ratio is presently 0.1 days. Approximately 2.3% of the shares of the stock are sold short.
View Benitec Biopharma's Short Interest
.

How were Benitec Biopharma's earnings last quarter?

Benitec Biopharma Inc. (NASDAQ:BNTC) announced its quarterly earnings data on Tuesday, February, 9th. The biotechnology company reported ($151.26) EPS for the quarter.
View Benitec Biopharma's earnings history
.

How has Benitec Biopharma's stock price been impacted by COVID-19?

Benitec Biopharma's stock was trading at $3.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BNTC stock has decreased by 24.0% and is now trading at $2.91.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for BNTC?

1 Wall Street analysts have issued 12-month price objectives for Benitec Biopharma's stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate Benitec Biopharma's stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 381.1% from the stock's current price.
View analysts' price targets for Benitec Biopharma
or view top-rated stocks among Wall Street analysts.

Who are Benitec Biopharma's key executives?

Benitec Biopharma's management team includes the following people:
  • Dr. Jerel A. Banks Ph.D., M.D., CEO & Exec. Chairman (Age 46, Pay $631.7k)
  • Ms. Megan Joan Boston, Exec. Director (Age 49, Pay $348.92k)
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist
  • Dr. Craig Lewis, Chief Medical Adviser
  • Dr. Claudia Kloth, Sr. VP of Manufacturing

Who are some of Benitec Biopharma's key competitors?

What other stocks do shareholders of Benitec Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), Amicus Therapeutics (FOLD), Sorrento Therapeutics (SRNE), Arbutus Biopharma (ABUS), Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL), BioLineRx (BLRX) and CRISPR Therapeutics (CRSP).

When did Benitec Biopharma IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is Benitec Biopharma's stock symbol?

Benitec Biopharma trades on the NASDAQ under the ticker symbol "BNTC."

Who are Benitec Biopharma's major shareholders?

Benitec Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.57%), Virtu Financial LLC (0.40%) and Warberg Asset Management LLC (0.90%).

Which major investors are buying Benitec Biopharma stock?

BNTC stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, and Warberg Asset Management LLC.

How do I buy shares of Benitec Biopharma?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Benitec Biopharma's stock price today?

One share of BNTC stock can currently be purchased for approximately $2.91.

How much money does Benitec Biopharma make?

Benitec Biopharma has a market capitalization of $14.02 million and generates $100,000.00 in revenue each year. The biotechnology company earns $-8,270,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis.

How many employees does Benitec Biopharma have?

Benitec Biopharma employs 14 workers across the globe.

What is Benitec Biopharma's official website?

The official website for Benitec Biopharma is www.benitec.com.

Where are Benitec Biopharma's headquarters?

Benitec Biopharma is headquartered at Level 14 114 William St, Melbourne C3, 3000.

How can I contact Benitec Biopharma?

Benitec Biopharma's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-8692-7222 or via email at [email protected]


This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.